Recap: Hologic Q3 Earnings

Shares of Hologic HOLX increased after the company reported Q3 results.

Quarterly Results

Earnings per share were up 77.33% year over year to $1.33, which beat the estimate of $1.12.

Revenue of $1,168,000,000 rose by 41.94% year over year, which beat the estimate of $1,040,000,000.

Outlook

Hologic Sees Q4 Adj. EPS $0.92-$1 vs $1.13 Estimate, Sales $1B-$1.04B vs $1.04B Est.

Conference Call Details

Date: Jul 28, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/vw522xit

Recent Stock Performance

Company's 52-week high was at $85.00

Company's 52-week low was at $56.81

Price action over last quarter: Up 8.88%

Company Overview

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!